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ABSTRACT
Detection of Shiga toxin-producing Escherichia coli (STEC) in The Netherlands is traditionally limited to
serogroup O157. To assess the relative importance of STEC, including non-O157 serogroups, stool
samples submitted nationwide for investigation of enteric pathogens or diarrhoea were screened with
real-time PCR for the presence of the Shiga toxin genes. Patients were selected if their stool contained
blood upon macroscopic examination, if they had a history of bloody diarrhoea, were diagnosed with
haemolytic uraemic syndrome, or were aged <6 years (irrespective of the bloody aspect of the stool).
PCR-positive stools were forwarded to a central laboratory for STEC isolation and typing. In total, 4069
stools were examined, with 68 (1.7%) positive PCR results. The highest prevalence was for stools
containing macroscopic blood (3.5%), followed by stools from patients with a history of bloody
diarrhoea (2.4%). Among young children, the prevalence (1.0%) was not signiﬁcantly higher than
among random, non-bloody, stool samples from diarrhoeal patients (1.4%). STEC strains were isolated
from 25 (38%) PCR-positive stools. Eleven O-serogroups were detected, including ﬁve STEC O157
strains. As serogroup O157 represented only 20% of the STEC isolates, laboratories should be
encouraged to use techniques enabling them to detect non-O157 serogroups, in parallel with culture, for
isolation and subsequent characterisation of STEC strains for public health surveillance and detection of
outbreaks.
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INTRODUCTION
Infections caused by Shiga-toxin producing Esch-
erichia coli (STEC) can range from mild, self-
limiting diarrhoea to severe diseases such as
haemorrhagic colitis and haemolytic uraemic
syndrome (HUS) [1]. Mortality, which occurs
mainly in the acute phase of HUS and long-term
renal disorders, end-stage renal disease and
diabetes, also occurs in a small proportion
of cases of HUS [2,3]. This causes a relatively
high average disease burden per case as com-
pared with other common enteric pathogens [4],
and, combined with the proven potential to cause
massive outbreaks, has placed STEC on the public
health agenda of many developed countries.
Gastroenteritis caused by STEC was very rare in
The Netherlands during the late 1990s, and was
dominated by STEC non-O157 strains rather than
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STEC O157 strains [5,6]. Exposure of humans to
STEC non-O157 strains is probably more frequent
because these strains are more prevalent among
animals and in food products than are STEC O157
strains [7,8].
Results from several European countries, using
expanded testing regimes that target all STEC
strains, have revealed that STEC non-O157 strains
are associated increasingly with diarrhoea and
HUS [9–13]. The continued predominance of
STEC O157 strains among cases of bloody
diarrhoea and HUS in the UK, Ireland and the
USA demonstrates that regional differences occur
[14–16], although this might still, in part, be a
diagnostic artefact. Outbreaks caused by STEC
non-O157 strains have been reported more regu-
larly in recent years [17–23].
Trend information concerning STEC in The
Netherlands is limited to non-sorbitol-fermenting
STECO157, as the traditional detection method for
STEC O157 involves culture on sorbitol MacCon-
key agar or on sorbitol MacConkey agar contain-
ing ceﬁxime and tellurite. In 2000, 88% of Dutch
medical microbiological laboratories used these
methods, and only 6% also tested for other STEC
serogroups [24]. Comparison of data concerning
Dutch cases of HUS during the early 1990s with
limited data for the year 2000 suggests that the
importance of STEC strains belonging to sero-
group O157 in diarrhoea-associated cases of HUS
might also be decreasing in The Netherlands (78%
vs. 63%) [25,26]. Rather than a particular O-sero-
group, the combined presence of Shiga toxin 2
(stx2 or stx2c) genes and, to a somewhat lesser
extent, the presence of the E. coli attaching and
effacing (eae) gene seem to be important predictors
of HUS [14,27–29]. To assess the current relative
importance of all STEC and, more speciﬁcally, of
non-O157 serogroups in The Netherlands, a
nationwide multicentre study was performed
between October 2005 and November 2006, using
standardised real-time (rt)-PCR assays.
MATERIALS AND METHODS
Study population
Eight large public health laboratories, representing all regions
of The Netherlands, with an estimated coverage of 5.2 million
inhabitants (32% of the population), participated in the study.
Between 24 October 2005 and 13 November 2006, stool
samples submitted to these laboratories for investigation of
enteric pathogens, or from evident diarrhoeal patients, were
screened for STEC using rt-PCR assays if the stool contained
blood upon macroscopic examination, if the patient had a
history of bloody diarrhoea, or if the patient was aged <6 years
(irrespective of the bloody aspect of the stool). The study
aimed to obtain four macroscopic bloody stools and ⁄ or stools
from patients with a history of bloody diarrhoea, and six
stools from children aged <6 years ⁄ laboratory ⁄week. Stool
samples from cases of HUS were also included. Thus, each
laboratory tested ten samples weekly, adding randomly
chosen stool samples from diarrhoeal patients who did not
meet the above criteria to complete this number.
Molecular screening for STEC
Molecular screening of the stool specimens for STEC was
performed as described previously [30], with minor modiﬁca-
tions. In brief, DNA was extracted using the NucliSens
miniMAG system (bioMe´rieux, Boxtel, The Netherlands) from
200 lL of a 20% w ⁄v faecal suspension in the presence of
c. 6000 copies of phocin herpes virus 1 (PhHV), and was eluted
in a ﬁnal volume of 100 lL. rt-PCR assays using TaqMan- or
LightCycler-based chemistries were performed as described
previously [30], using the following instruments: ABI
PRISM 7000 (three laboratories); ABI 7500 (two laboratories);
ABI PRISM 7900 (one laboratory) (Applied Biosystems, War-
rington, UK); LightCycler 1.5 (one laboratory); and Light-
Cycler 2.0 (one laboratory) (Roche Diagnostics Nederland BV,
Almere, The Netherlands). Stools that were positive by rt-PCR
were stored at 4C until transport to the central laboratory,
except during the ﬁrst 5 months of the study, when they were
stored at )20C. Storage conditions were changed because of
improved recovery of coliform bacteria at 4C as compared to
)20C during an experiment at one of the participating
laboratories (data not shown). Stools positive by rt-PCR were
also retested with the other rt-PCR platform (i.e., Taqman-
positive stools were retested with the LightCycler and vice
versa) to conﬁrm the results. Stool samples from two labora-
tories were also tested for the presence of the stx2f variant,
starting in September 2006 and October 2006, respectively.
Standardised overviews of the results were forwarded
weekly to the National Institute of Public Health and the
Environment (RIVM), Bilthoven, The Netherlands, for data
entry. Data forwarded included the rt-PCR STEC results, the
test values of positive and negative controls, the PhHV internal
control values, and results of tests for other possible enteric
pathogens in the stool. Inhibition of the TaqMan assay was
deﬁned as a cycle threshold (Ct) value of >33.7 (i.e., twice the
standard deviation above the mean value obtained after
running 676 samples), and inhibition of the LightCycler assay
was deﬁned as a crossing-point (Cp) value of >31.5 (i.e., twice
the standard deviation above the mean value obtained after
running 269 samples).
STEC isolation and typing
The stored stool samples that tested positive according to
rt-PCR were forwarded every month to the RIVM for STEC
isolation and, if this was successful, typing. Stools were
cultured on SSI Enteric medium (Statens Serum Institute,
Copenhagen, Denmark), on which E. coli appears as red
colonies and can be distinguished from other Enterobacteria-
ceae [31]. Putative E. coli colonies were tested by PCR for the
presence of the Shiga toxin 1 (stx1), Shiga toxin 2 (stx2), E. coli
attaching and effacing (eae) and enterohaemorrhagic E. coli
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haemolysin (ehly) genes [32]. Up to 50 colonies ⁄ stool sample
were screened in an attempt to isolate stx-positive colonies. If
no growth was observed on SSI Enteric medium, stool samples
were incubated in brain–heart infusion broth before culturing
on SSI Enteric medium. If stx-positive colonies were found, O-
and H-typing was performed for two randomly chosen stx-
positive colonies.
Clinical questionnaire
A brief standardised questionnaire was sent to the physician
requesting the test for all patients who were STEC-positive.
This questionnaire requested information concerning the
occurrence of symptoms, development of HUS, use of
antibiotics before stool sampling, hospitalisation, occurrence
of similar symptoms in household members in the week
before and after the patient’s onset of illness, place of
residence, and the main reasons for requesting laboratory
diagnostic tests.
Data analyses
All data from the laboratories and the clinical questionnaires
were entered in a Microsoft Access database and, together
with the typing data, exported to SAS v.9.1 software (SAS Inc.,
Cary, NC, USA) for further analysis. Frequencies were
calculated and cross-tabulations were made for descriptive
analysis. Differences in positivity rates among subgroups, or
sub-categories of categorical variables, were tested using chi-
square tests or Fisher’s exact test, as appropriate. Differences
for continuous variables were analysed using the Wilcoxon
rank sum test.
RESULTS
Collected stool samples, inhibition and positive
test results
In total, 4292 stool samples were examined during
the study period. PCR inhibition was observed in
223 (5.2%) stool samples, with PCR of samples
collected from patients with macroscopic bloody
stools or a history of bloody diarrhoea being
inhibited most often (9.6%). The stool samples
that showed PCR inhibition were excluded from
further analyses.
Overall, 68 (1.7%) of the remaining 4069 stool
samples yielded a positive result in the RT-PCR
assays (Table 1), with the prevalence ranging from
0.6% to 2.6% according to laboratory. The highest
prevalence was found in stools containing blood
upon macroscopic examination (3.5%), followed
by stools from patients with a history of bloody
diarrhoea (2.4%). The prevalence was no higher
among young children than among a random
sample of patients with non-bloody diarrhoea
(Table 1). Among children aged <6 years with a
history of bloody diarrhoea or a visibly bloody
stool, the prevalence was 1.5%. No signiﬁcant
association between the prevalence and the gen-
der or place of residence (degree of urbanisation)
was observed. Positivity rates ⁄month ranged
between 0% (February 2006) and 4.8% (November
2006), and were signiﬁcantly higher during the
period July–November 2006 than during the
period October 2005 - June 2006 (overall 2.7%
and 1.1%, respectively; p 0.0002) (Fig. 1).
For four positive stool samples, insufﬁcient
specimen remained for retesting using the alter-
native RT-PCR platform. For the other 64 samples,
the positive test result was conﬁrmed for 57
(89.1%) samples, consisting of 51 stool samples
and six DNA extracts. For the remaining seven
samples, six retests by LightCycler and one retest
by TaqMan were negative (median Ct ⁄Cp value
33.7). Two DNA extracts of the LightCycler-
negative retests were repeatedly positive in the
TaqMan assay, and an STEC strain was cultured
from the stool sample for one of these.
STEC-positive patients
Among the 68 STEC-positive patients, two
showed mixed infections with Campylobacter and
one with Yersinia. The clinical questionnaire was
returned for 62 (91%) of the patients. Common
symptoms were diarrhoea (85%), abdominal pain
(55%), abdominal cramps (50%) and blood in
stool (50%). Other symptoms, e.g., nausea (21%),
fever (19%), vomiting (13%) and decreased
diuresis or anuria (5%), were reported less often.
No cases of HUS were reported. Twelve (19%)
patients were hospitalised because of gastrointes-
tinal symptoms; one of these patients (an elderly
woman) was admitted to an intensive care unit
Table 1. Real-time PCR results for detection of Shiga
toxin-producing Escherichia coli (STEC), grouped according
to inclusion criterion
Criterion for inclusion in study
Tested Positive
n n %
Blood upon macroscopic examination 545 19 3.5
History of bloody diarrhoea 830 20 2.4
Either macroscopic blood or history of bloody diarrhoea 1267 37 2.9
Child aged <6 years 1865 18 1.0
Child aged <4 years 1421 13 0.9
Child aged <2 years 817 7 0.9
HUS patient 3 0 0
Random diarrhoeal stool sample 1059 15 1.4
Totala 4069 68 1.7
aCategories do not add up to 4069, as patients can have multiple inclusion criteria.
HUS, haemolytic uraemic syndrome.
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following surgery involving the small intestine,
caused by ischaemia. After a stay of 138 days in
the intensive care unit, this patient died because
of recurrent sepsis and renal failure. At least three
patients were known to suffer from colitis or
Crohn’s disease, one patient was diagnosed with
adenocarcinoma during the hospital stay, one
patient had a history of alcohol abuse, and one
terminal patient was diagnosed with systemic
amyloidosis.
Antibiotics were prescribed in 12 (19%) cases;
in seven cases, not for diarrhoeal disease, but for
other conditions, e.g., urosepsis, urinary tract
infection or respiratory infection. For four (24%)
of the 17 cases aged <6 years, similar symptoms
were reported for other household members (i.e.,
mother and father, mother, sister, brother, respec-
tively) in the 7-day period before or after the onset
of illness, compared with none of the cases aged
‡6 years.
The most common reasons for requesting lab-
oratory investigations were severity (35%) or
duration (32%) of symptoms (61% of requests
were for one or both reasons), or speciﬁc symp-
toms (25%), mainly blood in stool. A history
of foreign travel (destinations were Hungary,
Turkey, Morocco, Tunis and India) was reported
in 16% of the cases.
Two stool samples were lost during transport
to the RIVM. Isolation of the STEC strain was
successful for 25 (38%) of the 66 remaining stool
samples that were positive according to rt-PCR.
The Ct ⁄Cp values for the 41 rt-PCR stool samples
from which STEC was not isolated were signiﬁ-
cantly higher (median 29.5, 25th percentile 25.7,
75th percentile 35.0) than those for stool samples
that yielded STEC (median 24.0, 25th percentile
20.0, 75th percentile 29.5; Wilcoxon rank sum test,
p 0.01). For the stool samples where culture of
STEC failed, 11 showed no growth on SSI
medium or in brain–heart infusion broth, and 30
stool samples yielded no stx-positive colonies;
two of the latter category yielded stx-negative
eae-positive E. coli isolates (O136:H51 and O-non-
typeable:H49). Of the 11 stools that showed no
growth, seven (64%) had been stored at )20C
(38% of all stool samples tested were stored at
)20C). Eleven different O-serogroups were
revealed among the 25 STEC isolates, in addition
to some O-non-typeable STEC isolates. Most
common were O157 (n = 5), O103 (n = 3), O8
(n = 3), O26 (n = 2), O91 (n = 2) and O174 (n = 2)
(Table 2). The eae and ehly genes were present in
52% and 72% of the STEC isolates, respectively.
In this small subgroup of patients from whom
STEC was isolated, no association was revealed
between the presence of the eae and ehly genes
and an age of <6 years, and no signiﬁcant asso-
ciation was revealed for these virulence genes
with speciﬁc criteria for inclusion in the study,
except for a higher occurrence of the eae gene
among the eight STEC isolates from patients with
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Fig. 1. Percentage of stool samples positive ⁄month for Shiga toxin-producing Escherichia coli (STEC).
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macroscopic blood in stools (88% vs. 35% among
the 17 cases without macroscopic blood in stools;
Fisher’s exact test, p 0.03).
STEC with stx2f variant
Two laboratories that screened 211 stool samples
with primers and probes adapted to include the
stx2f variant sequence detected seven (3.3%)
STEC strains, three of which contained the stx2f
variant gene. These were from a boy aged 3 years
with uncomplicated diarrhoea and two adults
with a history of bloody diarrhoea, a male aged
47 years, and a female aged 66 years. One of the
adult stool samples was also culture-positive for
Campylobacter. In the other adult, an adenocarci-
noma of the rectum was diagnosed several
months later. For the child, no stool sample was
available for attempted isolation of STEC, but an
STEC O63:H6, eae-positive strain was isolated
from both adults.
Other enteric bacterial pathogens
Between 51% and 69% of the stool samples were
cultured for Campylobacter, Salmonella, Shigella or
Yersinia as part of the routine workup, with 8.4%,
4.8%, 0.2% and 0.1%, respectively, of the stool
samples yielding a positive result (Table 3). Over-
all, and for each inclusion criterion separately,
the prevalence of STEC was clearly less than the
prevalence of Salmonella and Campylobacter, but
was higher than the prevalence of Shigella and
Yersinia (Tables 1 and 3).
DISCUSSION
In this large-scale, nationwide study, the overall
STEC prevalence was 1.7%, ranging from 0.9%
for young children to 3.5% for patients with
macroscopic blood in their stool samples. These
results correspond well with results from the
limited number of similar studies published
Table 2. Distribution of O- and H-types and the presence of stx, eae and ehly genes among 25 Shiga toxin-producing
Escherichia coli (STEC) isolates from stool samples positive for STEC according to real-time PCR
O-type H-type stx1 stx2 eae ehly N Diarrhoeal aspecta
O8 H9 Neg Pos Neg Neg 2b B
O8 H19 Neg Pos Neg Neg 1 B
O26 H11 Pos Neg Pos Pos 2 1 B, 1 NB
O54 H21 Neg Pos Neg Neg 1 NB
O78 H- Pos Neg Neg Pos 1 B
O80 H- Neg Pos Pos Pos 1 NB
O91 H21 Pos Pos Neg Pos 1 NB
O91 H14 Pos Neg Neg Pos 1 NB
O103 H2 Pos Neg Pos Pos 3 B
O128 H2 Pos Neg Neg Neg 1 B
O146 H21 Pos ⁄Negc Pos Neg Pos 1 NB
O157 H7 Neg Pos Pos Pos 4 B
O157 H- Pos Pos Pos Pos 1 B
O174 H2 Pos Pos Neg Pos 1 B
O174 H8 Pos Pos Neg Neg 1 B
O-ntd H25 Pos Pos Pos Pos 1 B
O-ntd H16 Neg Pos Neg Neg 1 NB
O-ntd H25 Pos Neg Pos Pos 1 B
aB, bloody diarrhoea; NB, non-bloody diarrhoea.
bOne case was a mixed infection with Campylobacter.
cTwo different stx proﬁles were detected in the stool of the patient.
dO-nt, O-non-typeable with available antisera.
Pos, positive; Neg, negative.
Table 3. Detection by culture of other bacterial pathogens, grouped according to the same inclusion criterion used for stool
samples analysed for Shiga toxin-producing Escherichia coli
Criterion for inclusion in study Campylobacter (n = 2936) Salmonella (n = 2923) Shigella (n = 2894) Yersinia (n = 2228)
Blood upon macroscopic examination 68 (15.6) 44 (10.1) 3 (0.7) 0
History of bloody diarrhoea 123 (17.6) 58 (8.5) 2 (0.3) 0
Either macroscopic blood or history of diarrhoea 174 (16.7) 87 (8.5) 5 (0.5) 0
Child aged <6 years 53 (4.5) 59 (5.1) 0 2 (0.2)
Child aged <4 years 44 (4.9) 43 (4.8) 0 2 (0.3)
Child aged <2 years 19 (3.8) 14 (2.9) 0 0
Random diarrhoeal stool sample 39 (4.7) 15 (1.8) 1 (0.1) 0
Total 246 (8.4) 140 (4.8) 6 (0.2) 2 (0.1)
Values are given as n (%) positive.
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previously [9,16,33,34]. Among the STEC strains
isolated, the non-O157 isolates clearly predomi-
nated over the O157 serogroup. This has also been
observed in previous studies, in which the pro-
portions of non-O157 STEC isolates were 82%
and 64%, respectively [9,33]. Serogroups O26,
O103 and, to a lesser extent, serogroup O91
observed in the present study are well-recognised
non-O157 STEC strains in many other countries
[9,14,27,29,33,35–37]; however, serogroups O145
and O111, which are also among the most
common non-O157 serogroups worldwide
[9,11,14,16,27,29,33,35,37–39], were not detected
in the present study, although both types have
been found previously in some Dutch cases of
HUS and gastroenteritis [5,26], and the relative
importance of serogroup O111 appears to have
decreased in recent years [40]. In contrast, sero-
groups O8 and O174 have been observed only
sporadically in other countries [9,14,27,28,34–
36,41]. The high, almost exclusive, occurrence of
STEC O45 in the USA and STEC O117 in Den-
mark, which has been related mainly to travel to
developing countries, suggests that some circu-
lating types might be continent- or country-
speciﬁc [14,16,27,39]. Additional data are required
to determine whether the observed discrepancies
were a result of the small number of non-O157
isolates in the present study, or whether the
distribution of circulating types should indeed be
considered to be country-speciﬁc.
One limitation of using rt-PCR to screen stool
specimens for STEC is that this approach is
susceptible to PCR inhibition. An inhibition rate
of 5.2% was observed in the present study, but it
is of concern that inhibition was observed nearly
twice as often (9.6%) in the patient group with the
highest prevalence of STEC. Although these
specimens were regarded as inhibited, on the
basis of the criteria used, this does not mean that
the PCR data are not interpretable. Using the
quantitative nature of rt-PCR, the amount of
inhibition, and, consequently, its effect on the
analytical sensitivity, can be deduced from the
Ct ⁄Cp values for the PhHV internal control.
When the PhHV Ct/Cp values for the inhibited
specimens were considered, c.60% could be
interpreted at ten-fold reduced sensitivity, and
another 25% at 100-fold reduced sensitivity.
Taking into account the high sensitivity of both
rt-PCR assays, a small reduction in sensitivity is
probably acceptable. Inhibited specimens could
also be analysed by other detection methods, e.g.,
(rt-)PCR detection of (colony) sweeps of primary
cultures and ⁄ or antigen detection.
The relatively low success rate of 38% for
isolation of STEC by culture compared with
previous studies (75–97%) [16,28] may have been
caused by the use of PCR to target faeces directly
instead of using enrichment cultures of the (fresh)
stool as the starting point. The direct method was
chosen to limit costs for material and labour in the
participating clinical diagnostic laboratories, with
a future extensive testing strategy in mind. Alter-
natively, the isolation of STEC, based on typing of
individual colonies found to be positive for stx
genes according to conventional PCR, might be
hampered by the loss of stx genes over time
[42,43]. Storage duration, ranging from 1 week to
>8 weeks, and the change in storage temperature,
were not found to affect the STEC isolation rate.
A further study is required to compare the direct
faeces rt-PCR assay, combined with simultaneous
culture, with detection of STEC by rt-PCR of a
sweep and ⁄ or individual colonies on the plate.
Validation of the two assays used in this
multicentre study revealed that the LightCycler
assay was 1–2 log10 more sensitive than tradi-
tional culture on sorbitol MacConkey agar, but
between 0.35 and 1.11 log10 less sensitive than the
TaqMan assay [30]. The slightly lower sensitivity
of the LightCycler assay was supported by the
discrepant results obtained when retesting posi-
tive samples on the alternative rt-PCR platform.
Except in one case, it was not possible to prove by
culture that the discrepant results were true
STEC-positive samples, but it is unlikely that they
were all false-positive results, as the speciﬁcity of
both assays with regard to a large panel of
bacterial and fungal strains is excellent [30].
Consequently, the prevalence of STEC might have
been slightly underestimated, especially as the
prevalence seemed to be relatively high in labo-
ratories where the LightCycler assay was used
(2.1% vs. 1.5% in the laboratories where the
TaqMan assay was used).
The occurrence of STEC with the Shiga toxin
variant stx2f was clearly higher than expected
from previous reports, with an stx2f STEC strain
being found only once in 948 STEC patients with
diarrhoea or HUS from Germany during 1996–
2004 [44], and only once in 62 STEC patients from
England during 1983–2000 [29]. To date, serotypes
associated with stx2f in humans have been mainly
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O128ab:H) [29,45], and sporadically O145:H34
and O119:H) (F. Scheutz, personal communica-
tion). Thus, the O63:H6 serotype observed in the
present study is rather uncommon, even with the
classic stx genes [14,46]. In pigeons, from which
these STEC strains were ﬁrst isolated and which
are considered to be the natural reservoir for these
particular strains, other serotypes have also been
observed, e.g., O15, O18ab, O25, O45, O75 and
O152 [47]. Usually, stx2f (as stx1c, stx1d and stx2d)
genes are detected in isolates from human cases of
uncomplicated diarrhoea [29,44,45,48], and the
occurrence of bloody diarrhoea in the two adult
cases in the present study could be explained by
other causes, i.e., a co-infection with Campylobacter
and an adenocarcinoma. Many traditional PCR
assays, as well as several enzyme immunoassays,
are unable to detect all the different variants of
stx1 and stx2, which will lead to an underestimate
of the true occurrence of these variants [32,49,50].
Recently, an enzyme immunoassay capable of
detecting all known stx variants was described,
but the performance of this assay for use directly
on faeces was not assessed [51].
The observation of co-infections in 4.4% of the
STEC-positive patients is within the range
observed in previous large-scale studies of
gastroenteritis patients [5,6]. The occurrence of
severe co-morbidity in at least 11% of the cases
was remarkable, but it is not clear from previous
similar studies whether this observation is truly
unexpected. The seasonality of STEC in this
1-year study seemed similar, although less pro-
nounced, to the known seasonality of STEC O157,
with most cases being identiﬁed during summer
and autumn. Such moderate seasonal variation
has also been observed previously [9,14]. An
overall less severe clinical course in non-O157
STEC patients has been described previously
[28,39]. However, some non-O157 STEC strains,
e.g., O26, O103, O111 and O145, cause illness that
is at least as severe as that caused by STEC O157
[27,52]. Therefore, appropriate diagnostic assays
are required for patients with severe disease,
including HUS, and for those with serious
co-morbidity. Identiﬁcation of the toxins alone is
inadequate for public health surveillance and
should not be used to replace culture and sero-
typing completely.
In conclusion, STEC strains were found in
about one in 70 patients with uncomplicated
gastroenteritis, and were more common in
patients with a history of bloody diarrhoea, but
not in young children. STEC strains were detected
more often than Shigella and Yersinia, but less
frequently than Salmonella and Campylobacter.
Clinical laboratories are therefore advised to test
all specimens from individuals with diarrhoea for
STEC. However, if this is not considered to be
cost-effective or feasible, all stools from diarrhoeal
patients with either macroscopic blood in the
stool, a history of bloody diarrhoea or HUS
should be investigated. As serogroup O157 rep-
resented only 20% of the total STEC isolates,
laboratories in The Netherlands are encouraged to
use techniques that enable detection of non-O157
serogroups, in parallel with culture of Shiga
toxin-positive stools for isolation and subsequent
characterisation of the STEC strain for public
health surveillance purposes.
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